Revascularization and heart failure with preserved ejection fraction - time for randomized trials
- PMID: 35729798
- DOI: 10.1002/ejhf.2583
Revascularization and heart failure with preserved ejection fraction - time for randomized trials
Comment on
-
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study.Eur J Heart Fail. 2022 Aug;24(8):1427-1438. doi: 10.1002/ejhf.2446. Epub 2022 Mar 10. Eur J Heart Fail. 2022. PMID: 35119162
References
-
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61.
-
- Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1130-43.
-
- Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al.; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511-20.
-
- Perera D, Clayton T, Petrie MC, Greenwood JP, O'Kane PD, Evans R, et al. Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy. JACC Heart Fail. 2018;6:517-26.
-
- Deo SV, Reddy YNV, Zakeri R, Karnib M, Selvaganesan P, Elgudin Y, et al. Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study. Eur J Heart Fail. 2022;24:1427-38.